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According to the traditional view, atherosclerosis results from a passive buildup of cholesterol in the artery
wall. Yet, burgeoning evidence implicates inflammation and immune effector mechanisms in the pathogen-
esis of this disease. Both innate and adaptive immunity operate during atherogenesis and link many tradi-
tional risk factors to altered arterial functions. Inflammatory pathways have become targets in the quest
for novel preventive and therapeutic strategies against cardiovascular disease, a growing contributor to
morbidity and mortality worldwide. Here we review current experimental and clinical knowledge of the path-
ogenesis of atherosclerosis through an immunological lens and how host defense mechanisms essential for
survival of the species actually contribute to this chronic disease but also present new opportunities for its
mitigation.Introduction
Cardiovascular disease (CVD) has become the most frequent
cause of death globally (Murray et al., 2012). An estimated 17.3
million people die from CVD every year, equivalent to 30% of
all deaths worldwide. Low- and middle-income countries
currently suffer disproportionally, with more than 80% of all
CVD deaths occurring in such countries. In Western Europe
and North America, CVD mortality has declined due—at least
in part—to successful prevention and therapy, but it still remains
the most common cause of deaths in developed countries.
Although many diseases affect the cardiovascular system,
myocardial infarction (MI) and ischemic stroke caused by athero-
sclerosis dominate death and disability statistics for all regions of
the world.
Atherosclerosis affects large and medium-sized arteries. By
causing thrombosis or severe stenosis in arteries, it leads to
MI, ischemic stroke, ischemic damage to kidneys and intestines,
and many other life-threatening clinical manifestations (Libby,
2013). Before becoming clinically evident, the atherosclerotic
process progresses silently for years. Medical scientists there-
fore must not only address clinically manifest atherosclerotic
cardiovascular disease but also identify targets for prevention
and early treatment in apparently healthy individuals incubating
this insidious disease. Both these tasks require an understand-
ing of the pathogenesis of atherosclerosis.
According to the traditional view, atherosclerosis results from
a passive buildup of cholesterol in the artery wall. Accumula-
ting evidence implicates inflammation in the pathogenesis of
atherosclerosis, subject to major modulation by immune effector
mechanisms (Libby et al., 2011). A century ago, landmark
experiments by the Russian pathologist Nikolai Anitschkow
showed that cholesterol causes atherosclerosis in rabbits.
Epidemiological studies later identified an association between
plasma cholesterol concentrations and ischemic heart disease
in humans. Further research on cholesterol metabolism enabled
the preventive programs that now avert thousands of deaths
worldwide (Libby et al., 2000). In particular, the introduction of1092 Immunity 38, June 27, 2013 ª2013 Elsevier Inc.statins, a class of lipid-lowering drugs, has helped reduce
the incidence of MI by about a third (Mihaylova et al., 2012).
Emerging clinical evidence casts considerable doubt on inter-
ventions that target lipid fractions other than low-density lipopro-
tein (LDL), notable high-density lipoprotein (HDL, ‘‘good’’ choles-
terol), or triglycerides. Hence, pathogenic components beyond
the lipid profile have assumed major interest in therapeutic
attempts to address the substantial residual risk that persists
in the ‘‘statin era.’’
Inflammation, encompassing both innate and adaptive immu-
nity, characterizes atherogenesis and links many traditional risk
factors to altered function of arteries. Inflammatory pathways
have become the focus of intense research in the quest for
novel preventive and therapeutic strategies against CVD. Tech-
nological breakthroughs have offered excellent opportunities
for experimental studies with genetically engineered mice
that develop hypercholesterolemia and atherosclerosis, such
as mouse strains deficient in apolipoprotein E (Apoe/) or the
LDL receptor (Ldlr/). Technical advances have also permitted
identification of genes contributing to atherosclerotic cardiovas-
cular disease in humans, most recently by using genome-wide
association studies (GWASs) (Deloukas et al., 2013). Large clin-
ical trials and studies of population cohorts have also permitted
the evaluation of biomarkers and pathogenic factors in human
disease (Emerging Risk Factors Collaboration, 2012).
We review here current knowledge of the pathogenesis of
atherosclerosis through an immunological lens—first providing
insights from mice and then highlighting the gap between the
elegant experimental work in this species and the translation to
human disease. We then consider how host defense mecha-
nisms essential for survival actually contribute to chronic dis-
eases that threaten longevity such as atherosclerosis, and we
discuss the therapeutic perplex this paradox presents.
Macrophages, Pattern Recognition, and Cholesterol
Accumulation
Collections of lipid-laden macrophages characterize the athero-
sclerotic plaque.When plasma concentrations of cholesterol rise
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cles infiltrate the artery wall and tarry there as a result of interac-
tions with proteoglycans of the extracellular matrix. Local cellular
responses prompt expression of leukocyte adhesion molecules
on the endothelial lining of the artery, as well as expression of
chemokines by the vascular cells (Mestas and Ley, 2008; Weber
and Noels, 2011). These molecular stimuli recruit circulating
monocytes to enter the innermost layer of the artery (the tunica
intima), where they differentiate into macrophages upon stimula-
tion by mediators such as monocyte-colony stimulating factor
(M-CSF) produced locally (Clinton et al., 1992). The accumula-
tion of mononuclear phagocytes in the atherosclerotic lesion
depends not only on their influx, mediated by adhesion mole-
cules and chemoattractants, but also on retention within the
plaque. Recent work shows that netrin-1, a molecule implicated
in neuronal guidance produced in plaquemacrophages, acts in a
paracrine or autocrine manner to retain inflammatory cells in the
atheroma, acting by ligation of its receptor, UNC5b (Swirski
et al., 2012; van Gils et al., 2012).
Macrophage differentiation associates with increases in scav-
enger receptors (SRs) on the cells. These pattern recognition
receptors (PRRs) include the transmembrane proteins SR-A
(CD204), CD36, MARCO, and LOX-1 (OLR-1), which mediate
internalization of a broad range of molecules and particles
such as endotoxins, apoptotic bodies, parasite components,
and LDL particles. SRs can bind lipoprotein particles after they
undergo oxidative modification locally in the arterial wall. Mono-
nuclear phagocytes can also take up cholesterol by micropino-
cytosis of native LDL and phagocytosis of aggregated LDL
(Kruth, 1997, 2002). Eventually, cholesterol entry can overwhelm
the cell’s capacity for eliminating these molecules and choles-
terol starts to accumulate as cholesteryl ester droplets in the
cytosol. With time, the macrophages become overloaded with
cholesteryl ester droplets, taking on the characteristic ‘‘foam
cell’’ appearance. Many of these lipid-engorged phagocytes
eventually die, leading to accumulation of apoptotic bodies
and necrotic debris in the lesion, forming a ‘‘necrotic’’ core in
the evolving atheromatous lesion. Components of this detritus
can promote plaque progression and are prothrombotic.
Impaired clearance of such apoptotic debris (impaired efferocy-
tosis) may thus contribute to growth and thrombotic complica-
tions of atherosclerotic lesions (Moore and Tabas, 2011).
LDL Oxidation and Innate Immunity in Atherosclerosis
As oxidation confers on component LDL the ability to bind to
PRRs and favors foam-cell formation, much interest has focused
on LDL oxidation as a therapeutic target. Reactive oxygen spe-
cies (ROS) primarily attack double bonds in unsaturated fatty-
acid residues of triglycerides, phospholipids, and cholesteryl
esters. This process produces reactive molecular species that
can form adducts on polypeptide chains (e.g., malondialdehyde)
that typically generate crosslinks between free amino groups of
Lys and Arg residues. Such posttranslational changes of pro-
teins alter their functional and immunogenic properties (Miller
et al., 2011; Lichtman et al., 2013).
Some of the truncated lipids remaining after release of such
aldehydes have substantial biological activity. Thus, phosphoryl-
choline species generated after oxidative attack on phosphati-
dylcholine can activate endothelial cells to express leukocyte
adhesion molecules (Prescott et al., 2002). In addition, bothphosphorylcholine species and adduct-containing peptide
sequences may elicit antibody responses (see below).
Several enzymes can catalyze LDL oxidation. Blood activities
of some of these enzymes, including myeloperoxidase and
extracellular types of phospholipase A2 (sPLA2, Lp-PLA2),
associate with coronary artery disease (CAD) in some studies
(Quehenberger and Dennis, 2011). Pharmacologic inhibition or
genetic targeting of these enzymes reduces atherosclerosis in
mice. Yet, these enzymes have multiple effects, complicating
the interpretation of such experiments. For example, PLA2 can
exert platelet-activating factor acetylhydrolase activity that
degrades this prothrombotic and proinflammatory substance.
Nonenzymatic oxidants such as copper ions can also oxidize
LDL. Yet, endogenous antioxidants and buffering mechanisms
for transition metal ions render such reactions unlikely to occur
in blood. Attempts at preventing CAD events by antioxidant
administration have proven disappointing. Although some ani-
mal experiments and small-scale clinical trials showed promise,
large clinical trials with vitamin C and/or vitamin E, folate,
carotenoids, and a small molecule antioxidant drug have not
confirmed these benefits (Tardif et al., 2008). Although LDL
oxidation likely occurs in the atherosclerotic plaque, these pro-
cesses have not to date proven suitable as therapeutic targets.
Cholesterol Accumulation Activates the Inflammasome
When cholesterol accumulates in macrophages, crystals can
form. Cholesterol crystal formation in macrophages depends
on uptake, the intracellular balance between free cholesterol
and cholesterol ester, and cholesterol efflux to extracellular
acceptors such as apolipoproteins E or AI (Kellner-Weibel et al.,
1999). Such intracellular microcrystals can activate a member
of the cytosolic-nucleotide binding domain and leucine-rich
repeat gene family (NLRP3), activating its associated inflamma-
some, and promote processing of the proform of interleukin-1b
(IL-1b) into a bioactive cytokine (Duewell et al., 2010; Rajama¨ki
et al., 2010). Just as uric acid crystals in joints can cause
gout, cholesterol crystals in plaques can incite inflammation
in the artery wall. Genetic targeting of either IL-1b or a compo-
nent in the NLRP3 inflammasome reduces atherosclerosis in
mice, supporting a pathogenic role for this pathway of inflamma-
tory activation (Duewell et al., 2010). Thus, inflammasome
activation provides a possible pathogenic pathway that links
cholesterol accumulation to the chronic inflammatory process
of atherosclerosis.
Pattern-Recognition Receptor Activation
in Atherosclerosis
Several types of PRRsmay participate in atherogenesis. Beyond
cytosolic NOD-like receptors, components of inflammasomes,
cells in human atheromata express Toll-like receptor (TLR) family
members. Several experiments that use gene-targeted mice
have addressed the role of TLRs in atherogenesis, yielding rather
complex results (Curtiss and Tobias, 2009). TLR2 and TLR4
appear proatherogenic, whereas TLR3, TLR7, and TLR9 may
protect against atherosclerosis in mice. TLR2 presents a partic-
ularly complex situation because its expression on vascular
endothelium appears to promote atherosclerosis, whereas it
has protective effects when expressed by myeloid cells (Mullick
et al., 2008). Similarly, it is unclear why cell surface exposed
TLR2 and TLR4 are proatherogenic, whereas TLR3, TLR7, and
TLR9—all of which reside on intracellular membranes—protectImmunity 38, June 27, 2013 ª2013 Elsevier Inc. 1093
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MyD88 functions as an adaptor protein for all TLRs (except
TLR3) and of the IL1 signaling receptor. Activation of MyD88
via TLR ligation ultimately unleashes the NF-kB pathway that or-
chestrates the expression of many inflammatory agonists impli-
cated in atherogenesis. Targeted deletion of MyD88 shows a
much more pronounced effect of MyD88 on atherosclerosis
than interruption of TLR4 itself (Michelsen et al., 2004). This result
implies that TLR4-independent pathways for MyD88 activation
also contribute substantially to atherogenesis. Furthermore, se-
lective MyD88 deletion in dendritic cells (DCs) enhanced athero-
sclerosis, reflecting a requirement or TLR signaling in these
antigen-presenting cells (APCs) to induce atheroprotection
mediated by regulatory T cells (Subramanian et al., 2013).
The distinct effects of different TLRs may relate to their roles
in host defense. Several molecules and particles present in the
extracellular space may ligate TLR4, including oxidized LDL
particles and heat shock protein 60 (Hsp60) (Bae et al., 2009;
Cohen-Sfady et al., 2005). The ligands of intracellular TLRs
include endogenous and pathogen-derived nucleic acids, and
certain lipids implicated in atherogenesis, including free fatty
acids.
Genetic studies have addressed directly the role of TLR4 in
human cardiovascular disease. Point mutations at Asp299Gly
and Thr399Ile may render TLR4 less effective at binding lipo-
polysaccharide (LPS), in turn causing hyporesponsiveness to
endotoxins. Initial reports linked these mutations to less cardio-
vascular disease, suggesting that TLR4 signaling promotes
atherosclerosis in humans. Subsequent studies, however, did
not show that these variants protect against MI, and some
observations even suggested a disease-promoting effect of a
hyporesponsive TLR4 allele, as summarized in a recent metaa-
nalysis (Zhang et al., 2012). Thus, although mouse experiments
point to the operation of PRRs in atherosclerosis, their impor-
tance in human disease remains unclear.
Heterogeneity of Mononuclear Phagocytes
in Atherosclerosis
The foregoing discussion presumes that all mononuclear phago-
cytes serve similar functions. Recent results, however, provide
strong evidence to the contrary. The phosphatidylinositol-linked
cell surface protein known as Ly6c or Gr-1 distinguishes two
major subpopulations of mouse monocytes (Table 1). Normal
mice, and those that bear mutations rendering susceptibility
to diet-induced atherosclerosis, have under basal conditions
relatively few circulating monocytes, approximately evenly
distributed between the Ly6chi and Ly6clo populations. After initi-
ating an atherogenic diet, the blood of hypercholesterolemic
mice shows a dramatic increase in Ly6chi monocytes (Swirski
et al., 2007) (Tacke et al., 2007). This monocyte subpopulation
exhibits a series of functions that would render them particularly
pathogenic in the context of a chronic inflammatory disease
such as atherosclerosis. For example, these cells bind with
high avidity to activated endothelial monolayers. They express
higher amounts of proinflammatory cytokines and proteases
implicated in the pathogenesis of atherosclerosis than their
Ly6clo counterparts.
Cells derived from this proinflammatory population of mono-
cytes appear to home to nascent atheromata in mice in a
manner that depends on the chemokine receptor CCR21094 Immunity 38, June 27, 2013 ª2013 Elsevier Inc.(CD192)—the major ligand of which, monocyte chemoattractant
protein-1 (MCP-1), abounds in human and murine atheromata.
Hypercholesterolemia induces a Ly6chi monocytosis not only
in peripheral blood but also in the spleen. Indeed, hypercholes-
terolemic mice have an expanded population of Ly6chi mono-
cytes in a subcapsular pool in the splenic red pulp (Swirski
et al., 2009). These proinflammatory monocytes arise from ex-
tramedullary hematopoiesis in this locale. IL-3 and granulocyte
monocyte-CSF (GM-CSF) appear to drive expansion of bone-
marrow-derived macrophage DC precursors in the spleen
(Robbins et al., 2012). Endoplasmic reticulum stress related
to intracellular lipid accumulation in leukocytes may also
contribute to extramedullary hematopoiesis in the spleen of hy-
percholesterolemic mice (Westerterp et al., 2012). Proinflamma-
tory monocytes of splenic origin comprise up to a quarter of the
mononuclear phagocytes in mouse atheromata (Robbins et al.,
2012).
Systemic inflammation or ‘‘stress’’ mediated by the sympa-
thetic nervous system (in particular, beta-3 adrenergic stimula-
tion) can mobilize bone marrow progenitor cells to the spleen,
where they propagate to form a pool of proinflammatory
monocytes. This observation has particular relevance to acute
MI, a condition characterized by adrenergic activation due to
pain and anxiety. Cells from this splenic population home to sites
of acute injury, such as infarcts of the heart or brain, as well as
to sites of chronic inflammation, such as atheroma in mice
(Dutta et al., 2012). The human monocyte population that corre-
sponds to the Ly6chi population in mice remains controversial,
but the CD14+ CD16 population in humans may subserve this
function.
A body of literature identifies a predominance of the M1 sub-
population of macrophages in atheromata (Johnson and Newby,
2009; Sto¨ger et al., 2012). These classically activated macro-
phages can arise from monocytes in response to the cytokine
interferon-g (IFN-g) combined with a TLR stimulus and elaborate
mediators associated with the progression and complication of
atherosclerosis. Their less inflammatory counterparts, the M2
macrophages, may in contrast elaborate mediators that mitigate
atherosclerosis. Whether the Ly6chi population of monocytes
preferentially gives rise to M1 macrophages remains in-
completely substantiated. The polarization between monocyte
and macrophage subtypes in humans appears much hazier in
humans than in mice, raising a note of caution in facile extra-
polations from murine atherosclerosis to the human disease
(Table 1; Raes et al., 2005).
Mast Cells in Atherosclerosis
Mast cells do accumulate in human atheromata, particularly at
sites of plaque rupture. These cells, classically involved in al-
lergy and defense against parasites, also exhibit functions
that could contribute to atherogenesis in vitro (Kovanen,
2007). The conjectures regarding their causal role in aspects
of atherogenesis remained unsubstantiated until recently.
Both pharmacologic and genetic approaches currently sup-
port a contribution of mast cells to experimental atheroscle-
rosis in mice (Sun et al., 2007; Bot et al., 2007). In mice with
genetic deficiency of mast cells, adoptive transfer experiments
that reconstituted mast cell populations from mice with defi-
ciencies in particular cytokines point to proatherogenic roles
of mast-cell-derived IFN-g and IL-6 in the pathogenesis of
Table 1. Roles of Selected Cells, Mediators, and Biomarkers of Immune Mechanisms in Atherosclerosis
Role in Mouse Atherosclerosis Role in Human Atherosclerosis Comments
Cell Type
CD4+ Helper T Cells IFN-g-producing Th1 cells
predominate in lesions and
enhance lesion development
IFN-g-producing cells and dual
IFN-g+ IL-17-producing cells
frequent in lesions
Polarized Th cell subsets less
distinct in humans; effect of Th2
and Th17 cells is unclear
CD8+ Cytotoxic T Lymphocytes Relatively rare Present but less frequent than
CD4+ Th cells
May increase when T cell
inhibitory pathways are
impaired; overall proatherogenic
Regulatory T (Treg) cells CD25+ Foxp3+ Treg cells
atheroprotective; present but
less frequent as lesions progress
CD25+ Foxp3+ Treg cells present
but rare in advanced lesions
CD25 relation to Foxp3 less
constant in humans than in mice
B1 Lymphocytes Make natural antibodies specific
for Ox-LDL, which may be
atheroprotective
?
B2 Lymphocytes Found in adventitia of
atherosclerotic arteries
? Can be proatherogenic, perhaps
independent of antibody
secretion
Monocytes Proinflammatory Ly6Chi
Gr-1+ cells home to developing
lesions and presumably furnish
lesional macrophages
Human CD14hi CD16
proinflammatory monocyte
presumed source of lesinal
macrophages
Human and mouse subsets not
clearly comparable; precursors
of M1 macrophages not clear
Macrophages Major inflammatory cell in
lesions; mainly M1 slanted
Major inflammatory cell in
lesions; mainly M1 slanted
M1-M2 dichotomy not always
distinct, especially in humans
Granulocytes May be involved very early
in lesion development
No clear evidence of presence in
or role in development of lesions
Can accumulate in thrombi
Mast Cells Contribute to lesion
development
Participation in human plaques
less clear than in mice
Biomarker
High-sensitivity CRP (hsCRP) Expressed slightly, or not at all,
in mice
High hsCRP is a risk marker for
clinical disease
Basal blood CRP levels reflect
integrated overall inflammatory
burden; CRP likely not directly
involved in atherogenesis or
lesion complications
Anti-oxLDL antibodies Levels correlate with degree of
hypercholesterolemia and lesion
burden
Levels correlate with degree
of hypercholesterolemia and
clinical disease
Some anti-oxLDL antibodies
may be atheroprotective
Anti-oxHsp60 antibodies Levels correlate with degree of
hypercholesterolemia and lesion
burden
Levels correlate with degree
of hypercholesterolemia and
clinical disease
Immunity
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including chymase and tryptase may also participate in as-
pects of atherogenesis.
The Participation of Granulocytes in Atherosclerosis
Observations in human atheromata show relatively few polymor-
phonuclear leukocytes in undisrupted lesions. After plaques
rupture or erode, the thrombi that form in consequence can
entrap granulocytes and may form neutrophil extracellular traps
(NETS) (Megens et al., 2012). These cells release very high
amounts of ROS and the pro-oxidant enzyme myeloperoxidase.
Thus, the arrival of granulocytes on the scene of a disrupted pla-
que could aggravate local oxidative stress and amplify plaque
progression. Some mouse experiments provide support for
earlier involvement of polymorphonuclear leukocytes in murine
atherosclerosis (Drechsler et al., 2010; Weber et al., 2008). The
degree to which these mouse experiments apply to human
atherogenesis remains uncertain.Platelets as a Source of Inflammatory Mediators
Conventional concepts relegate platelets to a role in thrombus
formation. Ample experimental and clinical data substantiate
platelet participation in thrombosis. Yet, these particles also
contain abundant preformed proinflammatory mediators
including CD40 ligand (CD154), RANTES, and IL-6. Thus, plate-
lets constitute small ‘‘cluster bombs’’ of mediators of innate im-
munity (Croce and Libby, 2007). Upon activation—for example,
by thrombin—platelets spew forth these proinflammatory pro-
teins in copious amounts, also amplifying local inflammation
at sites of thrombus formation (Lievens and von Hundelshausen,
2011). In addition, platelets modulate T cell activation and
may therefore also impact adaptive immunity in atherosclerotic
lesions (Gerdes et al., 2011).
Complement Causes Controversy
Complement activation occurs in the atherosclerotic plaque.
Cleavage fragments of the complement cascade localize inImmunity 38, June 27, 2013 ª2013 Elsevier Inc. 1095
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lipid accumulation even in very early stages of disease (Seifert
et al., 1989). These findings prompted the question of whether
complement activation contributes to disease development.
Experimental studies have yielded contradictory results, how-
ever, with some suggesting a surprising, protective role for com-
plement activation through the classical and lectin pathways
(Torzewski and Bhakdi, 2013). Interestingly, the C3 cleavage
fragment C3a-desArg has important metabolic effects in adi-
pose tissue, where it promotes triglyceride synthesis. C3 activa-
tion may therefore affect atherosclerosis by modulating lipid
metabolism, aswell as vascular inflammation (Lewis et al., 2010).
GWASs have identified the complement factor C1q receptor
C1qRp (CD93) as a genetic risk factor for human cardiovascular
disease, and smaller genetic studies have associated defi-
ciencies in mannose-binding lectin (MBL) with increased coro-
nary and carotid artery disease. In prospective biomarker
studies, circulating concentrations of C1qRp, C3, C4, and C5a
predicted risk for future cardiovascular events. Thus, at least
some of the consequences of complement activation in plaque
may be atheroprotective rather than proatherosclerotic. The
mechanisms involved remain unclear.
Dendritic Cells Link Innate and Adaptive Immune
Responses
DCs derived from bone marrow precursors of the myeloid line-
age express many different PRRs, and populate most tissues
where they serve as sentinels of infection and injury. The intima
and adventitia of normal mouse and human arteries contain
DCs, and their numbers increase in atherosclerotic lesions
(Bobryshev, 2010; Cybulsky and Jongstra-Bilen, 2010; Ran-
dolph and Potteaux, 2010). DCs can internalize oxLDL and
become foam cells in vivo, and thus these cells likely participate
in inflammatory responses in early lesions (Packard et al., 2008).
DCs activated as part of an innate immune response in tissues
increase expression of the chemokine receptor CCR7, as well
as major histocompatibility complex (MHC) and costimulatory
molecules—changes that favor their migration into lymphoid
tissues and presentation of peptide antigens to naive T cells.
Therefore, recognition of PRR ligands primes DCs to initiate
T cell responses, a condition that likely pertains to proathero-
genic T cell responses (see below). In the absence of innate stim-
uli, so-called ‘‘immature’’ tissue DCs likely migrate constitutively
to lymphoid tissues and present healthy tissue antigens for
recognition by naive recirculating self-antigen-specific T cells.
The encounter of naive T cells with these immature DCs, which
express few costimulatory molecules, leads to T cell death,
anergy, or skewed differentiation toward a regulatory pro-
gram—all consequences that promote T cell tolerance to self.
Given the potential catastrophic consequences of active T cell
responses to antigens (self or foreign) in the arterial wall, vascular
DCs likely normally function to maintain tolerance to vascular-
wall antigens. This tolerogenic function of DCs provides a path
to immunotherapy of atherosclerosis, discussed later.
Clinical Observations Support a Role for Innate
Immunity in Human Atherosclerosis
The study of inflammation in human atherosclerosis has lagged
behind animal work due to obvious barriers. Human studies do
not permit the experimental manipulations that have enabled
routine exploration of mechanisms in mice—hence the need to1096 Immunity 38, June 27, 2013 ª2013 Elsevier Inc.turn to indirect approaches to test hypotheses regarding the
role of inflammation in human atherosclerosis. The application
of biomarkers of inflammation has proven enormously informa-
tive in this regard (Table 1). In particular, the pentraxin C-reactive
protein (CRP), an acute phase reactant, has proven particularly
useful as a biomarker of inflammation in clinical studies (Libby
et al., 2011). Classic inflammatory diseases such as acute infec-
tions and autoimmune diseases such as rheumatoid arthritis
associate with elevated concentrations of this primarily hepato-
cyte-derived protein.
A wealth of studies have now established that more modest
increases in CRP, measured with a high-sensitivity assay
(denoted hsCRP), predict first and recurrent cardiovascular
events in a way that adds prognostic information to conventional
risk biomarkers (Emerging Risk Factors Collaboration, 2012;
Kaptoge et al., 2010; Wennberg et al., 2012). Hepatocytes
synthesize CRP in response to stimulation by IL-6. Although
probably not a causal risk factor for atherosclerosis like LDL,
CRP serves as a useful biomarker of inflammatory status. CRP
lacks diurnal variation, has a relatively long half-life, and has an
inexpensive and reliable assay. Thus, this integrated marker of
inflammation has furnished an informative window on the
relationship between inflammation and cardiovascular events,
even though it may not itself mediate disease.
CRP elevations above the median not only foretell future car-
diovascular events such asMI or stroke, but also identify a group
of individuals who benefit from statin therapy despite having
average or below average blood concentrations of LDL choles-
terol (Ridker et al., 2008). The use of CRP provided clinical vali-
dation of the concept, which emerged from laboratory investiga-
tions that statins exhibit direct anti-inflammatory effects,
independent of their LDL-lowering properties (Ridker et al.,
2009). Considerable evidence supports anti-inflammatory ac-
tions of the statin class of drugs attributable to impaired prenyla-
tion of several cellular targets, including small G proteins such as
Ras, Rac, or Rho (Bu et al., 2011). Statins also augment the
expression of transcription factors such as Kru¨ppel-like factor-
2, which promotes the transcription of a cassette of genes that
can exert antiatherosclerotic and antithrombotic properties
(Sen-Banerjee et al., 2005).
Large clinical trials currently underway will test the proposition
that direct anti-inflammatory interventions that do not affect LDL
concentrations can prevent recurrent events in individuals who
have sustained a MI. The interventions currently under evalua-
tion include methotrexate in low weekly doses and amonoclonal
antibody that neutralizes the proinflammatory cytokine IL-1b
(Everett et al., 2013; Ridker et al., 2011). IL-1markedly stimulates
IL-6 gene expression, the driver of hepatic CRP production. In
addition, inflammasome activation by cholesterol crystals within
plaques provides a stimulus to local production of active IL-1b,
providing additional rationale for this therapeutic intervention.
Two other large clinical trials will test whether administration
of an inhibitor of lipoprotein-associated phospholipase A2
(LpPLA2), a potential generator of proinflammatory lipids in pla-
ques, will improve outcomes of patients with CAD (O’Donoghue
et al., 2011; White et al., 2010). While this LpPLA2 inhibitor atten-
uated inflammation in pig atheromata (Wilensky et al., 2008), the
agent did not lower CRP in a phase II trial, raising questions
regarding its anti-inflammatory action in humans (Serruys
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lipase apparently did not meet its primary endpoint (Nicholls
et al., 2012).
Atherosclerosis as a T Cell–Driven Disease
Several lines of evidence point to the operation of adaptive
immunity in human atherosclerosis. Plaques contain T cells,
including some that bear markers of activation (Hansson and
Jonasson, 2009; Jonasson et al., 1985, 1986), and autoanti-
bodies to LDL circulate in atherosclerotic patients (Hartvigsen
et al., 2008). The rapid occurrence of arteriopathy in human
hearts transplanted across major histocompatibility barriers,
sometimes in the absence of classical risk factors for atheroscle-
rosis, underscores the potential of alloimmune responses to pro-
duce intimal disease in humans that recapitulates some features
of atherosclerosis (Libby, 2012; Salomon et al., 1991). Such
observations led to the hypothesis that components of adaptive
immunity aggravate and modulate disease development. Sub-
sequent studies in animals, in particular the gene-targeted
mouse, support this hypothesis and offer insights into an intri-
cate and nuanced network of immune regulation in atherogen-
esis (Mallat et al., 2008).
The advanced human atherosclerotic plaque contains T cells,
largely effector-memory cells of which a substantial proportion
display signs of activation. About two-thirds of human plaque
T cells bear CD4 and the balance CD8, whereas CD4+ T cells
dominate in atherosclerotic mice. T cells of human lesions
exhibit a T helper-1 (Th1) cell-associated cytokine secretion
pattern, including IFN-g and tumor necrosis factor (TNF), and
mouse experiments have demonstrated important proathero-
genic effects of Th1 cells and their cytokines (Frostega˚rd
et al., 1999). As in other conditions, T cells of human atheroscle-
rotic plaques do not show the same degree of polarization as
those of inbred mouse strains, but Th1 cytokines do prevail
and arise from a larger number of T cells in human plaques
than do Th2 cell effector cytokines (in mice, typically IL-4,
IL-5, and IL-13) (Table 1).
The signature Th1 cytokine, IFN-g, promotes atherogenesis in
mice. Thus, targeted deletion of IFN-g or its receptor leads to
reduced disease, whereas administration of recombinant cyto-
kine protein aggravates atherosclerosis in hypercholesterolemic
mice (Gupta et al., 1997; Whitman et al., 2000). Interference
with IFN-g signaling also blocks allograft arteriopathy in mice
(Nagano et al., 1997). Several molecular targets may contribute
to such an effect of IFN-g. It inhibits proliferation and collagen
production by vascular smooth muscle cells (SMCs), thus im-
pairing repair processes in the vessel wall and possibly reducing
plaque stability (Amento et al., 1991). Furthermore, IFN-g ham-
pers cholesterol efflux frommacrophages and affects scavenger
receptor expression. This cytokine also promotes hyperglyce-
mia and increases fat inflammation, conditions thought to
enhance the risk of atherosclerotic cardiovascular disease
(Rocha et al., 2008).
The role of Th17 cells and their cytokines in atherosclerosis
has undergone intense study, yielding mixed results (Cheng
et al., 2011; Pober, 2011; Smith et al., 2010). Th17 T cells
seem to lack decisive influence on mouse atherosclerosis, in
contrast to Th1 cells, although they may modulate lesion forma-
tion and composition. In contrast, studies of Th2 cells do not
support a major role for this subset in atherosclerosis. Indeed,Th2 cells and their characteristic cytokines may promote forma-
tion of arterial aneurysms rather than intimal proliferative lesions
characteristic of atherosclerosis (Shimizu et al., 2004).
In humans, a CD28 null subset of CD4+ T cells expands in the
setting of chronic inflammatory diseases, cytomegalovirus infec-
tion, or advanced age. These cells elaborate many proinflamma-
tory cytokines and exhibit cytotoxicity. CD28 null CD4+ T cells
localize in unstable human lesions and, after MI, these cells
increase in peripheral blood (Liuzzo et al., 2007). The CD28 null
T cells in CAD patients exhibit an oligoclonal pattern of T cell
receptor (TCR) gene usage, and many react with HSP60, sug-
gesting they represent a population of effector cells expanded
by one or a few antigens. Furthermore, after isolation from blood,
these cells resist regulatory T (Treg) cell suppression in vitro.
Members of the TNF family signaling system (e.g., OX40) may
activate CD28 null T cells (Dumitriu et al., 2012). Yet, evidence
of the causal participation of CD28 null T cells in human athero-
sclerosis remains speculative. Mice do not have an equivalent
population of T cells.
Natural killer T (NKT) cells have particular interest for athero-
sclerosis, as they recognize lipid antigen and localize in lesions
both in mice and in humans (albeit at lower abundance). The
invariant NKT cell undergoes activation when lipid antigens
bound to CD1d ligate its Vbeta14+ TCR. Human atheromata
contain cells that displayCD1 (Melia´n et al., 1999). Administration
of a model antigen presented via CD1, a-galactosylceramide,
significantly accelerates early atherosclerosis in hypercholester-
olemic mice. Production of a set of proinflammatory cytokines
that include IFN-g and TNF (Tupin et al., 2004) and expression
of MHC molecules and leukocyte adhesion molecules in lesions
accompany this aggravation of atherosclerosis. Indeed, CD1d
deficiency results in reduced disease in atherosclerosis-prone
mice. In accordance with these findings, mice with CD1d-defi-
cient leukocytes display reduced atherosclerosis—suggesting
that endogenous lipid antigens, or possibly those derived from
the host microbiome, promote atherosclerosis via recognition
by NKT cells (VanderLaan et al., 2007). Several ongoing studies
aim to identify such molecules.
Counterbalancing Factors in Adaptive Immune
Responses in Atherosclerosis
Adaptive immunity can operate during atherogenesis as a ‘‘dou-
ble-edged sword,’’ exerting both exacerbating and inhibitory
influences on lesion development. Two anti-inflammatory cyto-
kines, IL-10 and transforming growth factor-beta (TGF-b), modu-
late atherogenesis in hypercholesterolemic mice (Mallat et al.,
1999; Lutgens et al., 2002). Eliminating TGF-b signaling to
T cells dramatically accelerated experimental atherosclerosis
(Robertson et al., 2003). These findings pointed to the subset
of regulatory T cells (Treg), which act at least in part by controlling
effector T cells, an important atheroprotective cell population
(Taleb et al., 2008). In support of this notion, transfer of iso-
lated CD4+CD25+ cells containing natural Treg cells reduced
atherosclerosis and counteracted the proatherosclerotic effect
of Treg cell deficiency (Ait-Oufella et al., 2006). Elimination of
FoxP3+ Treg cells with a diphtheria toxin receptor expression
strategy in hypercholesterolemic mice buttressed this concept
(Klingenberg et al., 2013).
Subsequent work pointed to Treg cells as important mediators
of atheroprotective effects of vaccines (Maron et al., 2002). TregImmunity 38, June 27, 2013 ª2013 Elsevier Inc. 1097
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elimination also yields delayed clearance of cholesterol-rich
lipoproteins and elevated plasma cholesterol concentrations
(Klingenberg et al., 2013). Elimination of Treg cells unmasks
the capacity of Th1 effector cells to suppress lipoprotein recep-
tors such as sortilin-1 on hepatocytes (Klingenberg et al., 2013).
These findings highlight the complex roles of Th1 cells in CVD
because Th1 cells can exert functions that either promote or
attenuate atherosclerosis.
As for other T cell subsets, evidence supporting Treg cell
actions in atherogenesis in humans has lagged that in mice.
Furthermore, effector T cell subsets may not be as distinct or
phenotypically stable in humans (Nussenblatt et al., 2010).
Indeed, many T cells isolated from human atherosclerotic coro-
nary arteries produce both IL-17 and IFN-g, as occurs in other
human and mouse tissues affected by autoimmune disease
(Eid et al., 2009). Overall, the limited data available for human
atherosclerosis support a proatherosclerotic role for Th1 cells
and support the operation of atheroprotective adaptive immune
mechanisms, but we lack detailed knowledge in this regard.
Costimulatory and coinhibitory pathways profoundly influ-
ence T cell responses to proteins by enhancing or inhibiting
antigen-driven T cell activation (Lichtman et al., 2013). The
most thoroughly studied of these pathways involve members
of the B7 family of costimulators, expressed on APCs, which
bind to the CD28 family of signaling receptors on T cells. Ther-
apeutics currently in use for treatment of autoimmune disease,
allograft rejections, and cancer target these molecules. The
same pathways influence atherosclerosis in mice. For example,
deletion of the genes encoding B7-1 (CD80) and B7-2 (CD86),
the costimulatory ligands of CD28, enhances lesion formation
in Ldlr/ mice (Buono et al., 2004). Conversely, deletion of
the genes encoding the coinhibitory molecules PD-L1
(CD274) and PD-L2 (CD273) or their receptor PD-1 (CD269)
enhances lesion formation and T cell infiltration in Ldlr/
mice. Targeted deletions of TNF-TNR superfamily costimula-
tory pathways, including OX40 Ligand-OX40 (CD134) and
CD137L-CD137, also reduce murine atherosclerosis (Jeon
et al., 2010; Nakano et al., 2010).
The development of natural and probably induced Treg cells
also requires costimulation. Bone marrow chimeric Ldlr/
mice deficient in the B7:CD28 or ICOS Ligand-ICOS pathways
have reduced Treg cells and develop more atherosclerosis
and more lesion inflammation than control mice (Afek et al.,
2005; Gotsman et al., 2006). Although these chimeric mice
have proven instructive in demonstrating the atheroprotective
role of Treg cells, there is no evidence that clinical costimula-
tory blockade, discussed below, reduces Treg cell mediated
suppression of or promotes T cell-mediated aggravation of
atherosclerosis.
Targeting costimulatory pathways to treat human disease has
proven feasible, as exemplified by the use of CTLA-4-Ig, a B7-1-
and B7-2-blocking drug used clinically to inhibit T cell responses
in patients with autoimmunity or renal allograft rejection. (Licht-
man et al., 2013) Costimulatory blockade can increase the fre-
quency of infections, which may limit this approach for CVD to
short-term interventions, such as patients with acute coronary
syndromes. An antibody blocker of the CD28 family coinhibitor
CTLA-4 has received approval to enhance antitumor T cell1098 Immunity 38, June 27, 2013 ª2013 Elsevier Inc.responses, and blockers of PD1 to treat cancer or chronic viral
infections are in clinical trials. These drugs that inhibit the T cell
inhibitors increase the risk of autoimmunity and would be pre-
dicted to aggravate atherosclerosis, as does anti-PD-1 in
Ldlr/ mice. Clinically useful agonists of the coinhibitory path-
ways await development.
The Antigen-Presenting Capacity of Arterial-Wall Cells
and Immunoprivilege of the Tunica Media
In addition to bone-marrow-derived ‘‘professional’’ APCs,
intrinsic vascular-wall cells themselves may participate in anti-
gen presentation in human vascular diseases (Pober and Tell-
ides, 2012). In particular, endothelial cells, which form the crucial
interface between the vessel wall and the blood compartment,
can present antigens effectively to T lymphocytes. Curiously,
human SMCs present antigens to T cells poorly, if at all (Murray
et al., 1995). SMCs lack the costimulatory molecule OX40L, one
contributor to their inefficacy as APCs (Zhang et al., 2010). The
ability of SMCs to produce indoleamine dioxygenase (IDO) likely
also contributes to the differential capacity of human endothelial
cells and SMCs to act as APCs. Heightened catabolism of tryp-
tophan by IDO can impair local T cell responses (Cuffy et al.,
2007). This finding has provided mechanistic basis for the
‘‘immunoprivilege’’ of the middle layer of the artery wall known
as the tunica media, a locale populated primarily by SMCs (Dal
Canto et al., 2001). IFN-g, a product of activated T cells, can
augment IDO activity in SMCs, furnishing another level of control
that may limit the propagation of adaptive immune responses to
intimal antigens beyond the vessel wall (Sakash et al., 2002). The
clinical significance of these interesting biological observations
awaits full explication.
Antigens Implicated in Instigating Adaptive Immunity
in Atherosclerosis
The operation of adaptive immune responses, both cellular and
humoral, implies an antigenic stimulus as a driver of atheroscle-
rosis. Indeed, two candidate autoantigens—LDL and Hsp60—
have emerged based on human studies and animal experiments
(Stemme et al., 1995; Xu et al., 1992).
The cytosolic chaperonin Hsp60 has a high degree of homol-
ogy to similar proteins in prokaryotic pathogens. CVD patients
and hypercholesterolemic animals have antibodies and T cell
responses to Hsp60. Endothelial cells exposed to hemodynamic
or metabolic stress express Hsp60 in a manner that may expose
it to the immune system, leading to autoimmune attack on the
vessel wall. Early experiments in rabbits and mice reported
that immunization against Hsp60 or homologous mycobacterial
Hsp65 aggravates atherosclerosis (Xu et al., 1992). More recent
studies in gene-targeted mice show that immunization against
this antigen may lead to a protective immune response with
increased Treg cell numbers, as well as antibody responses
concomitant with reduced disease (Afek et al., 2000; Klingen-
berg et al., 2012; Maron et al., 2002). Therefore, an immune
response to Hsp60 likely participates in the atherosclerotic pro-
cess, in humans as well as in animals. Yet, the details of Hsp
involvement remain enigmatic.
LDL itself is another putative autoantigen of atherosclerosis
(Figure 1). As the major vehicle for cholesterol transport and a
dominant risk factor for CVD, LDL participates causally in the
disease process. The LDL particle consists of a hydrophobic
core of esterified cholesterol and triglycerides covered by a shell
Figure 1. A Potential Role for Low-Density Lipoprotein as an Antigen that Promotes Atherosclerosis
Native LDL can undergo slight oxidativemodification that permits its uptake by PRRs on APCs (which may include DCs) but does not alter amino acid side chains
in ApoB sufficiently to interfere with immunogenicity. The ApoB-derived proteins, presented in the context of self MHC, with appropriate costimulation, stimulate
proliferation of the antigen-specific T cell clone and aggravation of atherogenesis.
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Reviewof polar phospholipids, free cholesterol, and a single copy of its
large signature apoprotein, the 550 kDa apolipoprotein B100
(apoB100).
Antibodies reactive to LDL components include natural immu-
noglobulin M (IgM) antibodies to its phospholipid components
but also high-affinity IgG antibodies to protein and lipid epitopes
(Miller et al., 2011). Antibodies reactive with the phosphorylcho-
line head of phosphatidylcholine, a prevalent phospholipid that
becomes exposed in oxidized, but not native LDL, constitute a
large proportion of all natural antibodies. Although the antigen-
binding sites of these antibodies have little diversity and low
affinity, exposure to an antigen can raise the titer of antiphos-
pholipid antibodies, as observed in patients infected with
T. pallidum. Similarly, antiphospholipid antibody titers increase
when hypercholesterolemic mice develop atherosclerosis.
B cell hydridomas established from nonimmunized, hypercho-
lesterolemic Apoe/ mice showed identity of some of these
spontaneous autoantibodies with certain natural antibodies
(Binder et al., 2008). Thus, the E06 anti-oxLDL antibody of
Apoe/ mice was identical to a natural IgA antibody called
T15. This anti-phosphorylcholine antibody binds not only to
oxLDL but also to phospholipids exposed on the surface
of apoptotic cells and to the cell wall of S. pneumoniae. This
observation implies that molecular mimicry operates between
autoimmune reactions to LDL and the immune response to
pneumococci. Immunization with heat-killed pneumococci
reduced the size of atherosclerotic lesions in hypercholesterol-
emic Ldlr/ mice; therefore, immunity directed against pneu-
mococcal phospholipids conveys partial protection against
atherosclerosis by molecular mimicry (Binder et al., 2003). This
finding agrees with previous observations that spleen B cells
carry atheroprotective immunity and that splenectomized
humans show increased cardiovascular morbidity (Robinette
and Fraumeni, 1977).
LDL evokes expansion not only of B1 cells producing natural
antibodies but also of B2 cells producing high-affinity IgG anti-
bodies. This response involves T cell help. Indeed, analysis of le-
sions from atherosclerotic patients and hypercholesterolemic
mice has identified T cells that recognize LDL epitopes. Interest-
ingly, T cells recognize ‘‘native’’ oligopeptide motifs of the
ApoB100 protein rather than oxidized ones, and extensive LDLoxidation extinguishes T cell reactivity (Figure 1; Hermansson
et al., 2010). Paradoxically, oxidation enhances uptake of LDL
into APCs through scavenger receptors. Therefore, an optimal
windowof oxidationmaygenerate autoimmunity to LDL,whereby
an LDL particle that has undergone minimal oxidation allows
uptake by APCs, but immunodominant T cell epitopes remain un-
oxidized, allowing T cells to recognize ApoB100 peptide-MHC
complexes on the APC surface (Figure 1). In support of this
conjecture, administration of antibodies to the Vb domain of
ApoB100 binding TCRs prevents anti-LDL immunity by blocking
the immunological synapse (Hermansson et al., 2010). This inter-
vention modulates not only cellular and humoral anti-LDL re-
sponses but also atherosclerotic lesion development.
The B Cell Balance in Atherogenesis
Accumulating data, primarily derived from atherosclerotic mice,
support a role for B cells in modulating atherogenesis. Initial
studies showed that hyperlipidemicmice have increased athero-
sclerosis following splenectomy (Caligiuri et al., 2002). Adoptive
transfer of B cells from splenectomized mice mutes the acceler-
ated atherogenesis. Nonselective B cell depletion achieved by
administration of an anti-CD20 antibody, however, reduces
murine atherosclerosis (Ait-Oufella et al., 2010). Subsequent
studies that use interruption of B cell activating factor (BAFF)
signaling point to a role for the B2 subpopulation of lymphocytes
in promoting atherogenesis in mice (Kyaw et al., 2013; Sage
et al., 2012). Current experimental evidence supports the view
that natural antibody derived fromB1 lymphocytes mutes exper-
imental atherogenesis (see below), whereas B2 cells aggravate
this process (Table 1). The B2 population appears to aggravate
atherogenesis through an antibody-independent mechanism
that augments the action of proinflammatory cytokines (Kyaw
et al., 2012). Thus, as in the case of T lymphocytes, distinct sub-
populations of B lymphocytes exert opposite effects on experi-
mental atherosclerosis. These observations suggest several
novel therapeutic avenues including manipulation of the cell
subpopulations with biological therapy and evoking natural anti-
body responses by vaccination, as discussed below (Nilsson
et al., 2013; Townsend et al., 2010). Although human atheromata
do contain some B lymphocytes, the applicability of the bur-
geoning results on B cell biology in mouse lesions to the human
situation remains uncertain.Immunity 38, June 27, 2013 ª2013 Elsevier Inc. 1099
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or Future Reality?
The identification of autoantigens led to the proposal that immu-
nization against them might alleviate disease (Amir et al., 2012;
Binder et al., 2007; Nilsson et al., 2013). The first immunization
study with oxLDL showed a remarkable, protective effect
against atherosclerosis, reducing lesion size in hypercholesterol-
emic rabbits by approximately 30% (Palinski et al., 1995).
Several other studies of rabbits and mice replicated this finding,
with reductions of lesions up to 60%. As discussed above, these
studies have implicated both cell-mediated and humoral effects
in the observed atheroprotection.
The LDL particle contains multiple lipid species and may bear
other apoproteins besides ApoB. In addition, LDL can transport
other hydrophobic or amphipathic molecules, such as endo-
toxins. Identification of the key antigens associated with the par-
ticle could spur the development of vaccination strategies. A
screen of LDL-derived peptides for immunogenicity has identi-
fied a set of peptides that were used for immunization (Pierides
et al., 2013). Some display protective effects and currently serve
to develop experimental vaccines. Studies are evaluating
different adjuvants and administration routes, such as mucosal
immunization with or without conjugation to the B subunit of
cholera toxin, subcutaneous administration with alum adjuvant,
and DC-based immunization (Hermansson et al., 2011; Klingen-
berg et al., 2010; Wigren et al., 2009). The lack of human leuko-
cyte antigen (HLA) restriction for atherosclerotic CVD in humans
presents a further conceptual challenge because T cell epitopes
may vary depending on the HLA alleles in each individual. There-
fore, an antiatherosclerosis vaccine may have to contain a com-
bination of immunogenic peptides in a suitable adjuvant. A
recent small clinical study of an anti-oxidized LDL antibody
monitoring glucose uptake in human atherosclerotic plaques
did not meet its primary endpoint (GLACIER, Goal of Oxidized
Ldl and Activated Macrophage Inhibition by Exposure to a Re-
combinant Antibody, http://www.clinicaltrials.gov/ct2/show/
NCT01258907?term=GLACIER&rank=1). The results of this
negative study await publication.
Ultimate proof of efficacy of novel therapies for atheroscle-
rosis requires large clinical trials that monitor endpoints such
asMI or ischemic stroke, not biomarkers such as glucose uptake
in plaque. Such outcome studies require daunting resources, a
consideration that limits the number of strategies that can
undergo such evaluation. Current progress regarding in vivo
imaging of atherosclerosis may open new opportunities for
monitoring human disease (Quillard and Libby, 2012). Such tech-
nologies would inform the design of clinical endpoint studies
immensely, both by guiding a rational choice of dosing regimen
and by providing biomarkers of efficacy in smaller populations
and shorter observation periods than required in clinical
endpoint trials. Imaging technologymay therefore catalyze prog-
ress in clinical applications of vascular immunology, not only with
regard to vaccines, but also to other therapeutic modalities.
Concluding Remarks
The evidence summarized above supports the operation of both
innate and adaptive immunity in atherosclerosis. Within the
realm of innate immunity, mononuclear phagocytes, as well
as mast cells, platelets, granulocytes, and the complement1100 Immunity 38, June 27, 2013 ª2013 Elsevier Inc.cascade, may all contribute to this disease. In the adaptive,
cellular immune response, T cells of several subtypes, antigen-
presenting DCs, and both B1 and B2 B cells and humoral immu-
nity exert modulatory effects on atherosclerosis.
Yet, the case for participation of inflammation and immunity
in human atherogenesis remains much less well substantiated
than in the elegant mouse experiments replete in the literature
(Table 1). Many of the convenient classifications of subsets of
cells with contrasting functions appear much more clear cut in
mice than in humans. Inbreeding of mice provides a degree of
genetic homogeneity unattainable in human studies. Moreover,
the laboratory environment may alter the microbiome in ways
that impact immune functions. The ‘‘hygiene hypothesis’’ high-
lights substantial differences between field mice, exposed to
multiple environmental stimuli, and the inbred strains of mice
we use experimentally, studiously protected from such condi-
tions (Devalapalli et al., 2006; Rook, 2010). Thus, humans exhibit
not only an enormous genetic diversity compared to mice but
also may experience environmental stimuli that could modulate
both adaptive and innate immunity in ways that differ from our
preferred species for laboratory experimentation. Recent work
suggests that the patterns of inflammatory gene responses in
inflammation differ drastically between humans and mice, with
concordance at random levels (Seok et al., 2013). As in the field
of immunology in general, the particular case of atherosclerosis
research requires a judicious interpretation of the experimental
literature when extrapolating its results to human disease.
The application of contemporary genetic tools may help close
the loop of causality in humans. GWASs and newer deep-
sequencing data have begun to identify associations between
variants in determinants of immune and inflammatory function
and atherosclerotic events in humans. The chemokine CXCL-
12 emerged in first-generation GWAS as associated with human
MI. The more recent CARDIoGRAMplusC4D Consortium GWAS
provided a network analysis that implicated inflammation as one
of the four pathways most strongly associated with human MI
(Deloukas et al., 2013). In particular, recent genetic studies
provide robust data linking the IL-6 receptor to coronary heart
disease (Sarwar et al., 2012).
Finally, application of the newfound appreciation of inflamma-
tion and immunity in atherosclerosis presents a clinical chal-
lenge. Global interference with these important host-defense
mechanisms can yield an immunosuppressed individual with
impaired tumor surveillance and increased susceptibility to
opportunistic infections. The splendid redundancy of immune
and inflammatory responses presents the challenge of identi-
fying particular mediators of these host-defense mechanisms
susceptible tomanipulation in amanner that canmitigate athero-
sclerosis without undue suppression of essential host-defense
mechanisms. Despite considerable progress in the understand-
ing of inflammation and immunity in this disease, harvesting its
fruits in terms of limiting human disease remains an aspiration
and important goal of future research.
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